Dysfunction of the intestinal mucosal immune system and dysbiosis of the intestinal
microflora can induce inflammatory bowel disease. However, drug-mediated clinical …

Oxidative stress is a key factor in the development of inflammatory diseases. Elimination of
reactive oxygen species (ROS) in the inflamed colon has been confirmed as an effective …

Repurposing clinically approved drugs to construct novel nanomedicines is currently a very
attractive therapeutic approach. Selective enrichment of anti-inflammatory drugs and …

Ulcerative colitis (UC) is featured with relapsing inflammation in the colon, where
macrophages are recruited and polarized locally into M1 type to drive further inflammation …

Abnormal activation of the gut mucosal immune system and a highly dysregulated gut
microbiota play essential roles in the progression of inflammatory bowel disease (IBD). The …

Ulcerative colitis (UC) is a chronic or relapsing inflammatory disease with limited therapeutic
outcomes. Pterostilbene (PSB) is a polyphenol-based anti-oxidant that has received …

Abstract Treatment for ulcerative colitis (UC) remains a clinical challenge as conventional
approaches mostly use immunosuppressive agents to ameliorate pro-inflammatory colonic …

Inflammatory bowel disease (IBD) is an idiopathic chronic inflammatory bowel disease
characterized by inflammation, intestinal barrier injury, and imbalance of gut microbiota …

Microbiota‐based therapeutics offer innovative strategies to treat inflammatory bowel
diseases (IBDs). However, the poor clinical outcome so far and the limited flexibility of the …

Inflammatory bowel disease (IBD) is a global public health challenge that affects millions of
people. Current medical treatments for IBD are not fully effective and may cause undesirable …